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Introduction: Basal-like breast cancer (BLBC) is an aggressive subtype often characterized by distant metastasis,
poor patient prognosis, and limited treatment options. Therefore, the discovery of alternative targets to restrain its
metastatic potential is urgently needed. In this study, we aimed to identify novel genes that drive metastasis of
BLBC and to elucidate the underlying mechanisms of action.
Methods: An unbiased approach using gene expression profiling of a BLBC progression model and in silico
leveraging of pre-existing tumor transcriptomes were used to uncover metastasis-promoting genes. Lentiviral-
mediated knockdown of interleukin-13 receptor alpha 2 (IL13Ralpha2) coupled with whole-body in vivo
bioluminescence imaging was performed to assess its role in regulating breast cancer tumor growth and lung
metastasis. Gene expression microarray analysis was followed by in vitro validation and cell migration assays to
elucidate the downstream molecular pathways involved in this process.
Results: We found that overexpression of the decoy receptor IL13Ralpha2 is significantly enriched in basal compared
with luminal primary breast tumors as well as in a subset of metastatic basal-B breast cancer cells. Importantly, breast
cancer patients with high-grade tumors and increased IL13Ralpha2 levels had significantly worse prognosis for
metastasis-free survival compared with patients with low expression. Depletion of IL13Ralpha2 in metastatic breast
cancer cells modestly delayed primary tumor growth but dramatically suppressed lung metastasis in vivo. Furthermore,
IL13Ralpha2 silencing was associated with enhanced IL-13-mediated phosphorylation of signal transducer and activator
of transcription 6 (STAT6) and impaired migratory ability of metastatic breast cancer cells. Interestingly, genome-wide
transcriptional analysis revealed that IL13Ralpha2 knockdown and IL-13 treatment cooperatively upregulated the
metastasis suppressor tumor protein 63 (TP63) in a STAT6-dependent manner. These observations are consistent with
increased metastasis-free survival of breast cancer patients with high levels of TP63 and STAT6 expression and suggest
that the STAT6-TP63 pathway could be involved in impairing metastatic dissemination of breast cancer cells to the
lungs.
Conclusion: Our findings indicate that IL13Ralpha2 could be used as a promising biomarker to predict patient
outcome and provide a rationale for assessing the efficacy of anti-IL13Ralpha2 therapies in a subset of highly
aggressive basal-like breast tumors as a strategy to prevent metastatic disease.* Correspondence: ppapageo@ucy.ac.cy; samthia@bu.edu; andreasc@ucy.ac.cy
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It is widely accepted that metastasis accounts for the
vast majority of deaths of patients with breast cancer.
Cancer metastasis represents a multistep event which
can be broadly divided in two phases: The first one rep-
resents the physical dissemination of cancer cells to
distant tissues, and the second involves the develop-
ment of macrometastatic lesions in these organs [1].
These steps involve the sequential acquisition of genetic
and epigenetic alterations which provide a level of cel-
lular plasticity that is indispensable for the completion
of the metastatic process [2, 3]. It is also clear that
complex tumor-host cell interactions are critically im-
portant for the adaptation of cancer cells in a foreign
tissue microenvironment, which fosters macroscopic
colonization [4].
Interleukins (IL) comprise a superfamily of pleiotropi-
cally acting cytokines that are present in the tumor
microenvironment and are implicated in a wide variety
of immunomodulatory functions, including cell matur-
ation, proliferation, migration, and adhesion [5]. In
addition to cells of the immune system, it is becoming
increasingly clear that these cytokines can exert their ef-
fects on epithelial cancer cells in an autocrine or para-
crine fashion, thereby regulating tumorigenesis and
cancer metastasis [6–8]. Thus, the expression patterns of
cytokine receptors on cancer cells may alter their re-
sponse to the tumor microenvironment and influence
their tumorigenic and metastatic potential. IL-13 is a T
helper 2 (Th2) cell-derived cytokine that plays a pivotal
role in inflammation and immune system regulation [9].
It shares structural and biological similarities with IL-4
and is known to function by initially binding to IL13Rα1,
followed by recruitment and heterodimerization with
IL4Rα to transduce signaling predominantly via the
Janus kinase 2-signal transducer and activator of tran-
scription (JAK-STAT) pathway [10–12]. On the other
hand, IL13Rα2 is a high-affinity receptor for binding and
internalization of IL-13 which is unable to transduce
downstream signaling potentially because of its short
cytoplasmic domain [13]. Thus, IL13Rα2 can function as
a decoy receptor by competing with IL13Rα1 for ligand
binding in order to inhibit downstream STAT signaling
and IL-13 responses [14–17]. Interestingly, high IL13Rα2
expression levels have been associated with the develop-
ment of gliomas as well as head and neck cancers
[18, 19] and were also shown to promote invasion and
metastasis of pancreatic, ovarian, and colorectal cancers
[20–22]. Although a previous gene expression profiling
study indicated that IL13Rα2 is overexpressed in breast
tumors from patients who developed lung metastases
[23], its functional role and underlying mechanism of ac-
tion in breast cancer development and progression re-
main largely unknown.Despite much effort in recent years, the discovery of
critical mediators of breast cancer metastasis which could
also represent feasible targets for therapy is still a major
challenge, particularly for the aggressive basal-like subtype
tumors, the majority of which are classified as triple-
negative: estrogen receptor-/progesterone receptor-/hu-
man epidermal growth factor receptor 2-negative (ER−/PR
−/Her2−). Here, using unbiased gene expression profiling
of a well-described human basal-like breast cancer (BLBC)
model system, we identified IL13Rα2 as a potent driver of
breast cancer metastasis. We found high expression levels
of this receptor to be associated with basal compared with
luminal primary breast tumors and enriched in a subset of
metastatic basal-B breast cancer cells. Increased IL13Rα2
levels were also associated with poor metastasis-free sur-
vival of patients with breast cancer. Importantly, targeted
depletion of IL13Rα2 resulted in dramatic suppression of
lung metastasis formation in vivo that is likely to be attrib-
uted, at least in part, to STAT6-dependent induction of
tumor protein 63 (TP63) expression and suppression of
breast cancer cell migration.
Methods
Cell culture
MCF10A (MI), MCF10ATk1.cl2 (MII), MCF10CA1h
(MIII), and MCF10CA1a (MIV) breast cancer cell lines
were obtained from the Karmanos Cancer Institute
(Detroit, MI, USA) and maintained as previously
described [2]. SUM159, SKBR3, MDA-MB-361 cells were
a kind gift from Ramon Parsons, of Mount Sinai Hospital
(New York, NY, USA), and MDA-MB-231-LM2 cells
were a kind gift from Joan Massague, of Memorial
Sloan Kettering Cancer Center (MSKCC) (New York,
NY, USA). MDA-MB-231 cells were purchased from
ATCC (Manassas, VA, USA). These cells were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10 % fetal bovine serum (FBS).
Antibodies and reagents
Antibodies were purchased from the following sources:
goat anti-IL13Rα2 (R&D Systems, Minneapolis, MN, USA),
mouse anti-IL13Rα2, mouse anti-α-tubulin, and mouse
anti-GAPDH (Santa Cruz Biotechnology, Inc., Dallas, TX,
USA), STAT6, P-STAT1, P-STAT3, P-STAT5, P-STAT6
(S737), P-STAT6 (Y641), mouse anti-HA (Roche, Basel,
Switzerland), and anti-TP63α (Cell Signaling Technology,
Beverly, MA, USA). PCMV6 empty vector or pCMV6-
IL13Rα2-Myc-Flag constructs were purchased from
OriGene (Rockville, MD, USA).
RNA isolation, cDNA synthesis, and real-time polymerase
chain reaction
Total RNA was isolated by using Trizol (Invitrogen, part
of Thermo Fisher Scientific, Waltham, MA, USA), and
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and random hexamers (Invitrogen). Real-time polymer-
ase chain reaction (PCR) was performed by using
primers listed in Additional file 1. All protocols were
previously described [2].
Western blotting
Whole protein cell lysates were isolated by using radio-
immunoprecipitation assay buffer containing protease
and phosphatase inhibitors. Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) analysis
was performed as previously described [2]. All Western
blot experiments were independently performed at least
three times, and the representative images shown were
quantified by using ImageJ software.
Kaplan-Meier plotter analysis
Kaplan-Meier plotter [24], an in silico online tool, was
used to predict survival of breast cancer patients on the
basis of expression of candidate genes. Affymetrix gene
expression data from multiple annotated breast cancer
studies are combined into a single database from which
we queried for associations between expression of se-
lected genes and patient outcome [25].
Meta-analysis of the MSKCC primary breast tumor cohort
Associations between IL13Rα2 expression levels and ER
or PR or Her2 receptor or basal and luminal breast
tumor subtypes or patient prognosis were investigated
by performing meta-analysis of the MSKCC primary
breast tumor cohort, as previously published [23]. Breast
tumor subtypes were determined on the basis of the
expression of keratin 5 and keratin 17 (basal) or keratin
8 and keratin 18 (luminal) markers [26]. Tumors were
stratified on the basis of the median IL13Rα2 expression
levels in low- or high-expression groups. Chi-squared
analysis was performed to reveal associations between
the different above-mentioned tumor characteristics.
Cloning of small hairpin RNA-expressing vectors and viral
transduction
To generate lentiviral vectors expressing small hairpin
RNA (shRNAs) against IL13Rα2 and STAT6, we used
AgeI/EcoRI-digested pLKO.1-puro vector ligated with
58 base pair-oligos (listed in Additional files 1) [27].
Establishment of MIV and SUM159 cells stably express-
ing different shRNA constructs was performed by
lentiviral-mediated transduction. Briefly, 293T cells were
co-transfected with 5 μg pLKO-shScrambled or pLKO-
shIL13Rα2 #1 or #2 or pLKO-shSTAT6 #1 or #2 with 3
μg psPAX2 and 1 μg pMD2.G plasmids. After 48 h, MIV
or SUM159 cells were transduced with virus-containing
medium in the presence of 10 μg/ml polybrene, selected
with 2 μg/ml puromycin, and pooled for further assays.MIV cells stably expressing the luciferase gene (MIV-
Luc) were generated by co-transfection of pMSCV-Luc-
PGK-hygro retroviral vector (gift from Scott Lowe,
Addgene-8782) (4 μg) with pCL1-ampho packaging plas-
mid (4 μg) in 293T cells. Viral supernatant was used for
transduction of target cells by using polybrene. Trans-
duced cells were selected by using 100 μg/ml hygromy-
cin, and resistant cells were pooled for further assays.
Transient transfection assays
Transient transfection assays were performed by transfect-
ing MCF10A (MI) cells with 3 μg pCMV6 empty vector
or pCMV6-shIL13Rα2-Myc-Flag construct (OriGene)
along with 9 μl of X-tremeGene 9 transfection reagent
(Roche). Cells were allowed to grow for 48 h before vari-
ous treatments with IL-13.
Transwell migration assays
Chemotaxis migration assays were performed by using
six-well transwell plates containing 8.0 μm-pore mem-
brane (Corning, Corning, NY, USA). Serum-free
DMEM/F-12 (1 ml-control) or DMEM/F-12 +10 % FBS
medium (1 ml) was added in the bottom chamber, and
3×105 MIV-Luc-shSCR cells or MIV-Luc-shIL13Rα2#2
cells were resuspended in 1 ml of serum-free DMEM/
F-12 and plated on the upper insert membrane. Cells
were then treated with or without 20 ng/ml IL-13 for
48 h, fixed with methanol, and stained with trypan blue
(0.4 %). Migrated cells localized on the bottom membrane
surface were imaged and counted by using an Axiovert
200M inverted microscope (Carl Zeiss, Oberkochen,
Germany) (10× magnification, at least five fields per
condition).
Tumorigenesis and metastasis assays coupled with whole-
body in vivo bioluminescence imaging
In vivo studies were conducted at the facilities of Boston
University School of Medicine under animal protocol
AN-14844 approved by the Institutional Animal Care
and Use Committee. Tumorigenesis assays were per-
formed by subcutaneously injecting 6-week-old female
NOD.CB17-Prkdcscid/J mice (The Jackson Laboratory,
Bar Harbor, ME, USA) with 5×105 MIV-Luc-shSCR or
MIV-Luc-shIL13Rα2#2 cells suspended in 0.1 ml of
serum-free DMEM/F-12 medium. For metastasis assays,
mice were injected with 5×105 MIV-Luc-shSCR or MIV-
Luc-shIL13Rα2#2 cells via the lateral tail vein. The
growth rate of tumors in animal tissues was monitored
once a week by using whole-body in vivo biolumines-
cence imaging. Mice were anesthetized by inhalation of
2 % isofluorane, and D-luciferin (150 mg/kg) was
injected intraperitoneally 30 min prior to measurements.
The rate of photon flux (photons/square cm per sec)
was quantified by using an IVIS Spectrum imaging
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ing Image software. Mice bearing primary tumors were
euthanized when tumors reached approximately 1 cm in
diameter or became ulcerated. Mice developing lung
metastases were euthanized when they developed cach-
exia symptoms. Primary tumors and murine lungs were
excised for measurement of tumor weight and assess-
ment of lung metastasis formation, respectively. In vivo
tumorigenesis assay was performed four independent
times, whereas metastasis assays were independently
performed twice.Histological analysis and immunohistochemistry
Primary tumors or lungs were isolated from mice
injected with either MIV-Luc-shSCR or MIV-Luc-
shIL13Rα2#2 breast cancer cells, fixed in 4 % parafol-
maldehyde, and embedded in paraffin. Tissue sections
(10 μm thick) were performed by using a Leica
RM2125RT microtome (Leica Biosystems, Nussloch,
Germany), followed by staining with hematoxylin and
eosin (H&E) by using standard methodology. Immuno-
histochemical detection of mitotic cells and IL13Rα2
expression were generated by staining sections with
anti-Ki67 antibody (clone MIB1) and goat anti-IL13Rα2
(R&D Systems), respectively, followed by horseradish
peroxidase-conjugated secondary antibodies and coun-
terstained with H&E. Bright-field images of stained slides
were obtained by using an Axiovert 200M inverted
microscope.Microarray gene expression analysis
To identify downstream effectors of IL13Rα2, four bio-
logical conditions were used: (1) MIV-Luc-shSCR cells
mock-treated (− IL-13), (2) MIV-Luc-shSCR cells treated
with 20 ng/ml IL-13 for 16 h (+ IL-13), (3) MIV-Luc-
shIL13Rα2#2 (− IL-13), and (4) MIV-Luc-shIL13Rα2#2
(+ IL-13). Total RNA was isolated from two biological
replicates of each condition by using an RNeasy mini-kit
(Qiagen, Hilden, Germany). Hybridization and initial
analysis were performed by ATLAS Biolabs GmbH
(Berlin, Germany) by using GeneChip Human Exon
1.0ST arrays (Affymetrix, Santa Clara, CA, USA). Raw
data quality control and normalization were performed
by using the Affymetrix Expression Console, whereas
differentially expressed genes were determined with the
Affymetrix Transcriptome Analysis Console (one-way
analysis of variance P value of less than 0.05, fold change
of more than or less than 2, false discovery rate of less
than 0.05). Hierarchical clustering was performed with
the TreeView Software. The microarray data generated
are available from the National Center for Biotechnology
Information (NCBI) Gene Expression Omnibus [28]
under accession code GSE57677.Statistical analysis
Two-tailed unpaired Student’s t test was performed for
statistical analysis of real-time PCR, migration assays, and
Western blot analyses. For in vivo experiments, two-tailed
unpaired Student’s t test or Mann-Whitney test was
performed to assess statistical significance. All data are
presented as mean ± standard error and are representative
of at least three independent experiments, unless stated
otherwise. Chi-squared analysis was performed to investi-
gate associations between IL13Rα2 expression and various
primary breast tumor features of the MSKCC cohort.
P values of less than 0.05 were considered statistically
significant between the compared samples and are indi-
cated by the (*) symbol for P < 0.05, by (**) for P < 0.01, or
by (***) for P < 0.001 in respective figures.
Results
IL13Rα2 is overexpressed in metastatic breast cancer cells
and is associated with poor prognosis for metastasis-free
survival of patients with breast cancer
The lack of promising molecular targets against breast
cancer metastasis led us to design a strategy for the
identification of novel metastasis-promoting genes. To
this end, we exploited a well-established cell line model
system for breast cancer progression which is transcrip-
tionally classified under the basal-B subtype [2, 29]. It
consists of the MCF10A (MI) spontaneously immortal-
ized mammary epithelial cell line and three of its deriva-
tives, namely MII, MIII, and MIV, obtained after serial
passaging in nude mice [30]. These cell lines exhibit
distinct tumorigenic and metastatic properties when re-
implanted in immunodeficient mice; MI is non-
tumorigenic, MII forms benign hyperplastic lesions,
MIII forms low-grade, well-differentiated carcinomas,
whereas MIV develops high-grade, poorly differentiated
metastatic carcinomas [31]. To identify candidate genes
that promote breast cancer metastasis, we re-analyzed
our recently generated gene expression microarray data
from this cell line system [32]. We focused on cluster 9
containing 29 genes significantly upregulated in the
metastatic MIV compared with their non-metastatic
counterparts, the MII and MIII cell lines (Additional
file 2: Figure S1). This list of genes was filtered by using
an online tool which performs meta-analysis of publicly
available microarray datasets from patients with breast
cancer to generate Kaplan-Meier survival curves [25].
During this analysis, patients were separated into two
groups on the basis of the expression levels of each
gene, and the probability of metastasis-free survival
over time was calculated. We found that higher expres-
sion of 10 out of the 29 genes could individually predict
worse distant metastasis-free survival (DMFS) of pa-
tients with breast cancer (Additional file 3: Figure S2).
The expression pattern of these genes was then
Fig. 1 IL13Rα2 is overexpressed in metastatic basal-like breast cancers and is associated with poor survival. a Real-time polymerase chain reaction
analysis of the candidate metastasis-promoting genes SMTN, AGTPBP1, IL13Rα2, IGF2BP2, VEGFA, HMGCS1, TRIB3, INHBA, INSIG1, and TMEM97 to
examine their expression levels in the MI, MII, MIII, and MIV cells. *P < 0.05, **P < 0.01, ***P < 0.001. b Kaplan-Meier survival analysis for assessment
of distant metastasis-free survival (DMFS) based on tumor IL13RΑ2 expression in 135 patients with grade 1, 377 patients with grade 2, and 196
patients with grade 3 breast cancer [25]. Survival curves were generated by using the Kaplan-Meier Plotter online tool based on data stratified at
the lower quartile (lowest 25 % IL13Rα2 expression versus all others). Curves were compared by log-rank test. c Meta-analysis of the Memorial
Sloan Kettering Cancer Center primary breast tumor cohort [23] was performed to identify associations between IL13Rα2 expression levels and
basal versus luminal breast tumor subtypes; estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor 2 (Her2)
receptor status; and patient prognosis. Tumors were stratified on the basis of the median IL13Rα2 expression levels in low- or high-expression
groups. Breast tumor subtypes were determined on the basis of the expression of keratin 5 and keratin 17 (basal) or keratin 8 and keratin 18
(luminal) markers [26]. Statistical significance was assessed by using chi-squared analysis. *P < 0.05. IL13Rα2 interleukin-13 receptor alpha 2
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estingly, IL13Rα2 was the most highly upregulated gene in
metastatic MIV cells compared with its non-metastatic
counterparts (Fig. 1a). In addition, high IL13Rα2 expres-
sion could specifically predict metastasis-free survival ofFig. 2 Knockdown of IL13Rα2 enhances IL-13-mediated STAT6 phosphorylati
blot analysis was performed with whole cell lysates to assess phosphorylation
time polymerase chain reaction (ii) were performed in MIV cells stably transdu
small hairpin RNA oligos (#1 and #2) to measure shIL13Rα2 protein and mRNA
with 1 ng/ml IL-13 for 30 min, and Western blot analysis was performed with
STAT3 (Y705 and S727). Total STAT6 and α-tubulin protein levels were detecte
were treated with 1 ng/ml IL-13 for 30 min, and Western blot analysis was pe
(Y641). Total STAT6 and GAPDH protein levels were detected as loading contr
small hairpin RNA against interleukin-13 receptor alpha 2, shSCR scrambled smpatients with high- but not low-grade tumors (Fig. 1b),
suggesting that overexpression of this gene may be in-
volved in promoting the late stages of tumor progression.
To further support these findings, we performed a meta-
analysis of gene expression microarray data from theon. a MIV cells were treated with 20 ng/ml IL-13 for 30 min, and Western
levels of STAT1, STAT3, STAT5, and STAT6. b Western blot (i) and real-
ced with shSCR or shIL13Rα2 lentiviral vectors expressing two different
levels, respectively. c MIV-shSCR and MIV-shIL13Rα2#2 cells were treated
whole cell lysates to assess phosphorylation levels of STAT6 (Y641) and
d as loading controls. d SUM159-shSCR and SUM159- shIL13Rα2#2 cells
rformed with whole cell lysates to assess phosphorylation levels of STAT6
ols. IL-13 interleukin-13, IL13Rα2 interleukin-13 receptor alpha 2, shIL13Rα2
all hairpin RNA, STAT signal transducer and activator of transcription
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cated that high IL13Rα2 levels are significantly associated
with the basal compared with luminal tumor subtype as
well as bad prognosis. Increased IL13Rα2 expression
was also marginally associated with ER− breast tumors,
whereas no association was found with PR or Her2 status
(Fig. 1c). We also performed a meta-analysis of two add-
itional published microarray datasets from breast cancer
cell lines of various subtypes [29] as well as from meta-
static variants of MDA-MB-231 breast cancer cells [23].
Based on this analysis as well as on validation in a subset
of these cell lines by real-time PCR and Western blotting,
we found that IL13Rα2 overexpression is exclusively
enriched in a subset of basal-B breast cancer cells that are
highly metastatic to the lungs (MCF10CA1a, MDA-MB-
436, BT549, SUM159, and MDA-MB-231-LM2-4175) [23,
31, 33, 34] but not in any of the luminal or basal-A sub-
type cells (Additional file 4: Figure S3 and Additional file
5: Figure S4). Collectively, these data indicated that high
IL13Rα2 levels might be involved in metastatic progres-
sion of basal-like breast tumors.
IL13Rα2 depletion enhances IL-13-mediated STAT6
phosphorylation
It is well established that IL-13 can induce the phos-
phorylation and activation of various STAT protein fam-
ily members, in a context-dependent manner, to regulate
diverse cellular properties [35]. To investigate which is
the predominant STAT protein that is activated by IL-13
in our system, we treated MIV cells with IL-13 and ana-
lyzed the activation of STAT proteins. We found that
STAT6 was robustly phosphorylated at Tyr641 by IL-13
but that STAT3 phosphorylation at Tyr705 appeared to
be only modestly induced. In contrast, STAT3 (Ser737),
STAT5 (Tyr694), and STAT1 (Tyr701) residues were not
affected by IL-13 treatment (Fig. 2a). Because IL13Rα2
acts as a negative regulator of the IL-13 pathway, we
wanted to assess whether IL13Rα2 overexpression can
aberrantly regulate IL-13-mediated STAT signaling by
predominantly targeting STAT6. To obtain further in-
sights, we first confirmed that the IL13Rα2 protein and
mRNA are overexpressed in metastatic MIV compared
with non-metastatic MI, MII, and MIII cells (Additional
file 5: Figure S4a, S4b). Then, we constructed lentiviral
vectors expressing shRNA against IL13Rα2 and stably
knocked down IL13Rα2 expression in metastatic MIV
cells (Fig. 2b). Treatment of MIV-shSCR or MIV-
shIL13Rα2#2 cells with IL-13 followed by Western blot-
ting analysis revealed that, upon IL13Rα2 knockdown,
there was a significant increase in the level of STAT6
phosphorylation mediated by IL-13 (Fig. 2c). To verify
that this effect is not cell line-specific, we also stably de-
pleted IL13Rα2 in SUM159 cells. Comparison between
SUM159-shSCR and SUM159-shIL13Rα2 cells indicatedthat there was a similar enhancement of STAT6 activa-
tion by IL-13 in the absence of IL13Rα2 (Fig. 2d). In
addition, we performed the reverse experiment by overex-
pressing IL13Rα2 in the non-tumorigenic MCF10A (MI)
cell line which resulted in inhibition of STAT6 activation
by IL-13 (Additional file 6: Figure S5a, S5b). Overall, these
data demonstrate that high levels of IL13Rα2 can suppress
IL-13-mediated STAT6 phosphorylation.
Knockdown of IL13Rα2 modestly delays primary breast
tumor growth and suppresses breast cancer metastasis
to the lungs
Because we found that targeting IL13Rα2 enhances
STAT6 phosphorylation by IL-13, we hypothesized that
this induction may be implicated in modulating the
tumorigenic and metastatic properties of breast cancer
cells. To address this question, we stably introduced a
luciferase reporter in MIV cells to monitor and quantify
the spatiotemporal growth of tumors, generated upon
injection of cells in immunodeficient mice, by non-
invasive whole-body bioluminescence imaging. First, we
performed in vivo tumorigenesis assays to compare the
effect of IL13Rα2 expression on the tumorigenic poten-
tial of MIV cells. MIV-Luc cells stably transduced with
either scrambled shRNA (MIV-Luc-shSCR) or shRNA
against IL13Rα2 (MIV-Luc-shIL13Rα2#2 cells) were sub-
cutaneously injected in non-obese diabetic/severe com-
bined immunodeficient (NOD/SCID) mice. We found
that there was a delay in the tumor growth of IL13Rα2-
depleted MIV-Luc cells compared with controls and that
this was attributed predominantly to a significant, albeit
modest, reduction during days 12–16 post-injection
(Fig. 3a, b). Consistent with these results, the weight of
tumors isolated from MIV-Luc-shIL13Rα2-injected cells
was found to be reduced compared with those from con-
trol cells (Fig. 3c). Subsequent immunohistochemical
analysis confirmed reduction of IL13Rα2 levels in tu-
mors, whereas H&E staining did not reveal any major
differences between shSCR and shIL13Rα2#2 primary
tumors. Both exhibited similar morphology indicative of
poorly differentiated carcinomas with cords and nests of
moderately sized malignant cells and showed nuclei dis-
playing focal nuclear pleomorphism (Fig. 3d). On the
other hand, Ki67 staining revealed modest reduction in
mitotic activity of IL13Rα2-depleted tumors consistent
with the corresponding reduction in tumor weight
(Fig. 3e).
Furthermore, to investigate whether overexpression of
IL13Rα2 is involved in breast cancer metastasis, we
performed in vivo metastasis assays by injecting MIV-
Luc-shSCR or MIV-Luc-shIL13Rα2#2 cells via the lateral
tail vein of NOD/SCID mice and quantified photon flux
weekly by bioluminescence imaging. All mice were
euthanized at 11 weeks post-injection, when control
Fig. 3 IL13Rα2 depletion delays growth of primary breast tumors. a Representative in vivo bioluminescence images of non-obese diabetic/severe
combined immunodeficient mice injected subcutaneously with 5×105 MIV-Luc-shSCR or MIV-Luc-shIL13Rα2#2 cells at different time points post-
implantation. b Quantification and comparison of photon flux (photons/sec per cm2) over time (Student’s t test, day 5 P value = 0.96, day 12 P
value = 0.0003, day 16 P value = 0.017 and day 22 P value = 0.042, n = 11). *P < 0.05, **P < 0.01, ***P < 0.001. c Comparison of primary tumor
weight between MIV-Luc-shSCR and MIV-Luc-shIL13Rα2#2 cell-derived tumors at the experimental endpoint 22 days post-implantation
(Student’s t test, P value = 0.0017, n = 15). **P < 0.01. Representative images (d) from hematoxylin and eosin (H&E), anti-IL13Rα2 (brown) and
(e) from anti-Ki67 staining (brown) of 10 μm-thick sections from paraffin-embedded primary tumors isolated from mice injected with MIV-Luc-
shSCR or MIV-Luc-shIL13Rα2#2 cells (20×). IL13Rα2 interleukin-13 receptor alpha 2, shIL13Rα2 small hairpin RNA against interleukin-13 receptor
alpha 2, shSCR scrambled small hairpin RNA
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were removed to assess the presence of metastatic col-
onies. Remarkably, we found that whereas mice injected
with the control MIV-Luc cells developed numerous
large metastatic nodules in the lungs, none of the mice
injected with the IL13Rα2-depleted MIV-Luc cells had
any visible signs of macrometastases. This was clearly
evident both by measuring the photon flux (Fig. 4a, b)
and by gross examination of internal organs, including
the lungs (Fig. 4c). Interestingly, histological analysis oc-
casionally revealed the presence of micrometastatic le-
sions in the lungs of mice injected with the MIV-Luc-
shIL13Rα2#2 cells (Fig. 4d). This evidence suggests that
knockdown of IL13Rα2 either impairs extravasation ofMIV cells in the lungs, or reduces survival in the circula-
tion, or suppresses the colonization of secondary organs.
Targeting IL13Rα2 induces TP63 expression and is
associated with suppression of breast cancer cell
migration
The dramatic suppression of lung metastasis formation
upon IL13Rα2 knockdown led us to investigate the mo-
lecular mechanisms underlying this phenomenon. Be-
cause MIV cells harbor gain of the 5q31 locus resulting
in an extra IL-13 gene copy [36], we hypothesized that
IL-13 stimulates these cells in vivo in an autocrine fash-
ion. First, we performed gene expression profiling of
MIV cells to identify the differentially expressed genes
Fig. 4 Targeting IL13Rα2 suppresses breast cancer metastasis to the lungs. a Representative endpoint (11 weeks) bioluminescence images of
non-obese diabetic/severe combined immunodeficient mice injected intravenously with 5×105 MIV-Luc-shSCR or MIV-Luc-shIL13Rα2#2 cells. b
Quantification of photon flux (photons/sec per cm2) and comparison of metastatic colonization in the lungs of mice injected with MIV-Luc-shSCR
or MIV-Luc-shIL13Rα2#2 cells (Mann-Whitney test, P value = 0.029, n = 4). *P < 0.05. c Representative images of lungs excised after euthanasia of mice
injected with MIV-Luc-shSCR or MIV-Luc-shIL13Rα2#2 cells. Yellow arrows depict the presence of large macrometastatic nodules. d Representative
images from hematoxylin-and-eosin staining of 10 μm-thick sections from paraffin-embedded lungs isolated from mice injected with MIV-Luc-shSCR
or MIV-Luc-shIL13Rα2#2 cells. Yellow arrow indicates the presence of a micrometastatic lesion in a lung from MIV-Luc-IL13Rα2#2-injected mice (10×
magnification). IL13Rα2 interleukin-13 receptor alpha 2, shIL13Rα2 small hairpin RNA against interleukin-13 receptor alpha 2, shSCR scrambled small
hairpin RNA
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IL-13 or both. Initially, we aimed to identify genes
which are transcriptionally regulated by IL-13 in breast
cancer cells. The comparison of expression patterns
between MIV-Luc-shSCR (− IL-13) and MIV-Luc-
shSCR (+ IL-13) led to the identification of 28 differen-
tially expressed genes (20 up- and 8 down-regulated)
(Additional file 11: Table S1). To define the genes
which are transcriptionally affected by high IL13Rα2
levels, we compared MIV-Luc-shSCR (− IL-13) and
MIV-Luc-shIL13Rα2#2 (− IL-13) cells and revealed 36
differentially expressed genes (29 up- and 7 downregu-
lated) (Additional file 12: Table S2). Because IL13Rα2
functions as a decoy receptor of IL-13 signaling, we
hypothesized that a subset of critically important genes
mediating the suppression of lung metastases are con-
trolled by this signaling cascade. To identify such genes
in our system, we performed unsupervised hierarchical
clustering by comparing the differentially expressed
genes between MIV-Luc-shSCR (− IL-13) and MIV-
Luc-shIL13Rα2#2 (+ IL-13) (Fig. 5a). Within the 52 dif-
ferentially expressed genes identified (36 up- and 16
downregulated), we selected six genes on the basis of
exhibiting the following distinct expression pattern,consistent with the role of IL13Rα2 as a negative regu-
lator of IL-13 signaling; for example, genes induced by
this pathway should be upregulated in both MIV-Luc-
shSCR (+ IL-13) and MIV-Luc-shIL13Rα2#2 (− IL-13)
compared with untreated control cells and their expres-
sion levels should be additively or further enhanced in
the MIV-Luc-shIL13Rα2#2 (+ IL-13) group. In
addition, the list of genes that were differentially
expressed on the basis of the pattern explained above
was further refined, and TP63, CFI, GPX2, SERPINB13,
MLLT3, and CXCL17 genes were finally selected for
validation by real-time PCR (Fig. 5b) on the basis of
their previously reported roles in cancer progression.
Interestingly, we found that the known metastasis
suppressor TP63 was among the top differentially
expressed genes, suggesting that it may be a down-
stream target of IL-13 signaling with functional impli-
cations. We also examined TP63 protein levels by
Western blotting and found that it is cooperatively in-
duced by IL13Rα2 knockdown and IL-13 in MIV cells
(Fig. 5c-i). To further support these findings, stable
depletion of IL13Rα2 in the metastatic basal-like
SUM159 cell line enhanced TP63 levels in a similar
manner (Fig. 5c-ii), whereas IL13Rα2 overexpression in
Fig. 5 IL-13 signaling induces expression of the metastasis suppressor TP63 and impairs cancer cell migration. a Heatmap showing the expression
pattern, in all biological groups, of the 52 differentially expressed genes (35 upregulated and 17 downregulated) between MIV-Luc-shSCR (− IL-13)
cells and MIV-Luc-shIL13Rα2#2 (+ IL-13, 20 ng/ml) cells. Values are expressed as log2-transformed. b Real-time PCR analysis for the validation of
TP63, CFI, GPX2, SERPINB13, MLLT3, and CXCL17 gene expression pattern. *P < 0.05, ***P < 0.001. c-i Western blotting analysis to assess the protein
expression pattern of TP63 in the above-described conditions in MIV cells. c-ii Real-time PCR analysis was performed to measure TP63 mRNA
levels in SUM159-shSCR or SUM159-shIL13Rα2#2 cells in the presence or absence of 20 ng/ml IL-13 for 24 h. *P < 0.05, ***P < 0.001. d Transwell
migration assays to quantify the migratory potential of MIV-Luc-shSCR and MIV-Luc-shIL13Rα2#2 cells in the presence or absence of 20 ng/ml IL-
13 for 48 h. *P < 0.05, **P < 0.01, ***P < 0.001. IL-13 interleukin-13, PCR polymerase chain reaction, shIL13Rα2 small hairpin RNA against interleukin-
13 receptor alpha 2, shSCR scrambled small hairpin RNA, TP63 tumor protein p63
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TP63 mRNA and protein expression (Additional file 6:
Figure S5c, S5d). Because decreased TP63 levels have
been associated with enhanced invasion and migration
as well as metastatic potential of cancer cells [37–39], we
hypothesized that, upon IL13Rα2 knockdown, IL-13 sig-
naling suppresses metastasis by impairing the ability of
breast cancer cells to migrate. To address this question,we performed transwell migration assays which confirmed
that IL13Rα2 depletion accompanied by IL-13 treatment
could additively reduce the migration rate of metastatic
MIV cells (Fig. 5d and Additional file 7: Figure S6). Im-
portantly, the decrease in the ability of breast cancer cells
to migrate was inversely proportional to TP63 expression
levels (Fig. 5b, c), consistent with the role of TP63 as a
suppressor of cell migration and metastasis. In contrast,
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proliferation (Additional file 8: Figure S7a), anchorage-
independent growth (Additional file 8: Figure S7b), or cell
death due to loss of extracellular anchorage (Additional
file 8: Figure S7c). Further supporting our in vitro find-
ings, direct inoculation of MIV-Luc-shSCR or MIV-
Luc-shIL13Rα2#2 cells in the right lung of NOD/SCID
mice did not reveal any major differences in tissue
colonization or survival between the two groups of ani-
mals (Additional file 9: Figure S8a, S8b). Collectively,
this evidence suggests that targeting IL13Rα2 is likely to
suppress metastasis, at least in part, by reducing cancer
cell migration and inhibiting extravasation to the lungs.
Activation of a STAT6-TP63 signaling axis by IL-13 is
associated with increased survival of patients with breast
cancer
Because our data indicated that IL-13 signaling in-
duces TP63 expression and that IL13Rα2 depletion en-
hances IL-13-mediated STAT6 phosphorylation, weFig. 6 An IL-13-STAT6-TP63 signaling axis is associated with improved su
transduced with shSCR or shSTAT6 lentiviral vectors expressing two differ
performed in to measure STAT6 protein levels. The protein levels of α-tub
were treated with 20 ng/ml IL-13 for 24 h, and real-time polymerase chai
STAT6 (b) (**P < 0.01, ***P < 0.001) or TP63 (c) (*P < 0.05). d Kaplan-Meier
based on combined expression of STAT6 and TP63. Survival curves were g
stratified based on the median. Curves were compared by log-rank test. D
scrambled small hairpin RNA, shSTAT6 small hairpin RNA against signal tra
activator of transcription 6, TP63 tumor protein p63hypothesized that TP63 upregulation could be linked
to STAT6 activation. To address whether STAT6 is
implicated in TP63 expression, we first stably knocked
down STAT6 in MIV cells and confirmed its decrease
in both mRNA and protein levels (Fig. 6a, b). Import-
antly, we found that although IL-13 was able to induce
TP63 expression in MIV-Luc-shSCR cells, this effect
was abolished upon STAT6 depletion (Fig. 6c). These
data indicated that IL-13-mediated TP63 transcription
is directly or indirectly dependent on STAT6. Finally,
based on this evidence, we hypothesized that if a me-
tastasis suppressing IL-13-STAT6-TP63 signaling axis
is activated in the absence of IL13Rα2 then STAT6
and TP63 expression levels may coordinately predict
survival of patients with breast cancer. Indeed,
Kaplan-Meier plotting analysis revealed that patients
with higher average expression of STAT6 and TP63
have significantly longer DMFS and relapse-free survival
(RFS) compared with patients with low expression levels
of these genes (Fig. 6d and Additional file 10: Figure S9).rvival of patients with breast cancer. a MIV cells were stably
ent small hairpin RNA oligos (#1 and #2). Western blotting was
ulin were used as loading control. MIV-shSCR and MIV-shSTAT6 cells
n reaction was performed to measure expression levels of either
analysis for assessment of DMFS in 1284 patients with breast cancer,
enerated by using the Kaplan-Meier Plotter online tool based on data
MFS distant metastasis-free survival, IL-13 interleukin-13, shSCR
nsducer and activator of transcription 6, STAT6, signal transducer and
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Metastasis is the major cause for the vast majority of
deaths of patients with breast cancer. BLBCs are among
the most aggressive subtypes and often share similar fea-
tures with triple-negative tumors. The common ineffect-
iveness of most available targeted therapies to treat
metastatic basal-like tumors highlights the urgent need
for the identification of new therapeutic targets. To
identify novel genes implicated in promoting breast can-
cer metastasis, we took advantage of a well-established
cell line system for BLBC progression. Gene expression
profiling of the model cell lines along with mining of
pre-existing tumor transcriptome data revealed that
IL13Rα2 overexpression is significantly associated with
basal compared with luminal tumor subtype as well as
bad prognosis and is also overexpressed in a subset of
highly metastatic basal-B cancer cell lines. Kaplan-Meier
survival analysis further indicated that increased
IL13Rα2 levels are associated with shorter metastasis-
free survival of patients with high-grade breast tumors.
Importantly, depletion of IL13Rα2 resulted in a modest
but consistent delay in primary tumor growth and dra-
matically suppressed lung metastasis formation in vivo.
Consistent with our findings, there is a growing list of
cancers in which overexpression of IL13Rα2 has been
reported to promote tumor progression, including glio-
blastoma, pancreatic, ovarian, and colon cancers, sug-
gesting a critical role for this alteration in a multitude of
cancers [18, 20–22].
To decipher the molecular basis for how targeting
IL13Rα2 suppressed breast cancer metastasis, we exam-
ined the phosphorylation status of STAT proteins and
found enhanced STAT6 phosphorylation as the major
downstream signaling mediator. Subsequent gene ex-
pression profiling of metastatic breast cancer cells profi-
cient or deficient in IL13Rα2, and treated with or
without IL-13, identified a subset of genes regulated by
the IL-13 signaling pathway. Interestingly, the known
metastasis suppressor gene TP63 was among the genes
found to be significantly upregulated by IL-13 in the
context of IL13Rα2 depletion. Previous studies have
shown that, whereas the truncated ΔNP63 isoform can
promote tumor growth [40, 41], loss of the full-length
TP63 expression enhances invasion and migration of
cancer cells as well as their ability to metastasize to dis-
tal organs [37–39]. Moreover, knockdown of STAT6
abolished the ability of IL-13 to induce TP63 expression,
suggesting that it is involved, directly or indirectly, in its
transcriptional activation. Consistent with the role of
TP63 as a suppressor of breast cancer cell migration, the
combination of IL13Rα2 depletion concomitant with IL-
13 treatment potently suppressed the migratory potential
of metastatic MIV cells. In contrast, the effect of
IL13Rα2 in regulating metastasis appears to beindependent of cell proliferation, anchorage-independent
growth, anoikis, or in vivo colonization to the lungs.
Therefore, the fact that depletion of STAT6 impaired
TP63 upregulation suggests that a STAT6-TP63 axis
may be involved, at least in part, in IL-13-mediated sup-
pression of cancer cell migration, extravasation, and
eventually metastasis. However, we cannot rule out the
possible involvement of other genes identified in our ex-
pression profiling analysis as candidates for suppressing
metastasis via the IL-13 pathway. It is noteworthy that
we identified not only genes previously reported to be
regulated by IL-13, such as CD36 [42, 43], SERPINB3,
and SERPINB4 [44], but also a number of other genes
that have not been previously connected to this pathway.
It is possible that some of these, such as the orphan che-
mokine CXCL17, recently shown to promote angiogen-
esis and cancer progression [45], could also be involved
in regulating metastatic dissemination via the IL-13
pathway. Additionally, among the known IL-13 regulated
genes, SERPINB13 is another legitimate candidate as its
low expression has been associated with poor clinical
outcome of head and neck cancers [46]. Additional func-
tional studies will be necessary to elucidate the potential
involvement of such candidate effector genes in meta-
static progression downstream of IL-13.
Overall, our studies resulted in the unbiased discovery
that IL13Rα2 overexpression is a major contributor to
metastatic progression in a subset of BLBCs. We also pro-
vide evidence, for the first time, for the existence of an
anti-migratory IL-13-STAT6-TP63 signaling axis that may
exert metastasis-suppressing effects on breast cancer cells.
This evidence is further supported by the Kaplan-Meier
survival plotting analysis which indicated that high levels
of STAT6 and TP63 expression were associated with lon-
ger DMFS of patients with breast cancer.Conclusions
Cell membrane receptors that facilitate breast cancer
metastasis represent an attractive group of accessible
molecular targets that could be exploited as the basis for
personalized therapy. Therefore, the discovery of
IL13Rα2 as an important mediator of metastatic disease
in a subset of aggressive BLBCs should be further evalu-
ated both as a biomarker and as a potentially important
therapeutic target for preventing cancer metastasis.
Additional files
Additional file 1: Supplementary materials and methods. Detailed
description of materials and methods used for experiments that are
described in the supplementary figures.
Additional file 2: Figure S1. Gene expression profiling of the MII, MIII,
and MIV cell lines. Heatmap showing the gene expression pattern
between MII, MII, and MIV breast cancer cells as we describe elsewhere
Papageorgis et al. Breast Cancer Research  (2015) 17:98 Page 13 of 15[32]. Adjacent heatmap focuses on cluster 9, which includes 29 genes
with higher expression levels in MIV compared with MIII and MII cells.
Heatmap colors indicate the z-score for the expression of each gene (red,
highest expression; blue, lowest expression).
Additional file 3: Figure S2. Kaplan-Meier survival plot analysis of
candidate metastasis-promoting genes. Kaplan-Meier survival plots were
generated by using the Kaplan-Meier Plotter online tool [24] based on
data stratified at either the lower quartile or the median expression of
each gene, as indicated. (a) Distant metastasis-free survival (DMFS)
analysis of patients for all breast cancers was calculated on the basis of
tumor IL13Rα2 expression for each of the following genes: SMTN,
AGTPBP1, IGF2BP2, VEGFA, HMGCS1, TRIB3, INSIG1, TMEM97, INHBA, and
IL13RA2. Curves were compared by log-rank test. (b) DMFS analysis of
patients for different tumor grades (1, 2, or 3) was calculated on the basis
of tumor IL13RA2 expression for each of the following genes: SMTN,
AGTPBP1, IGF2BP2, VEGFA, HMGCS1, TRIB3, INSIG1, TMEM97, and INHBA.
Curves were compared by log-rank test. IL13Rα2 interleukin-13 receptor
alpha 2.
Additional file 4: Figure S3. Meta-analysis of breast cancer cell line
gene expression. Meta-analysis of previously published microarray data
[23, 29] from 27 luminal, 12 basal-A, and 11 basal-B breast cancer cell
lines to assess the expression levels of IL13Rα2. Fold change in IL13Rα2
levels was calculated compared with the expression of the non-
tumorigenic MCF10A cell line. IL13Rα2 interleukin-13 receptor alpha 2.
Additional file 5: Figure S4. Evaluation of IL13Rα2 levels in breast
cancer cell lines. Western blotting analysis (a) and real-time PCR (b) were
performed to measure IL13Rα2 protein and mRNA levels, respectively, in
MI, MII, MIII, and MIV cells. (c) Western blotting analysis was performed to
measure basal IL13Rα2 protein in SUM159, parental MDA-MB-231, and
MDA-MB-231-LM2 cells. (d) Real-time PCR analysis to quantify IL13Rα2
mRNA levels in SKBR3, MCF7, MDA-MB-361, MDA-MB-231, SUM159, and
MDA-MB-231-LM2 cells. *P < 0.05, **P < 0.01, ***P < 0.001. IL13Rα2
interleukin-13 receptor alpha 2, ND not detected, PCR polymerase chain
reaction.
Additional file 6: Figure S5. IL13Rα2 overexpression suppresses IL-13-
mediated STAT6 phosphorylation and TP63 expression. (a) MCF10A (MI)
cells were transfected either empty pCMV6 vector or pCMV6- IL13Rα2-
Myc-Flag construct and 48 h post-transfection were either mock-treated
or treated with 20 ng/ml IL-13 for additional 24 h. Real-time PCR analysis
was performed to measure IL13Rα2 mRNA levels. (b) MCF10A (MI) cells
were transfected either empty pCMV6 vector or pCMV6- IL13Rα2-Myc-
Flag construct and 48 h post-transfection were either mock-treated or
treated with 1 ng/ml IL-13 for 30 min. Western blotting analysis was
performed in whole cell lysates to measure P-STAT6 (Y641) levels. Total
STAT6 and GAPDH protein levels were also measured as loading controls.
(c) MCF10A (MI) cells were transfected either empty pCMV6 vector or
pCMV6-IL13Rα2-Myc-Flag construct and 48 h post-transfection were
either mock-treated or treated with 20 ng/ml IL-13 for an additional 24 h.
Real-time PCR analysis (c) or Western blotting analysis (d) was performed
to measure TP63 mRNA or protein levels, respectively. Total STAT6 and
GAPDH protein levels were measured as loading controls where
indicated. IL-13 interleukin 13, IL13Rα2 interleukin-13 receptor alpha 2, PCR
polymerase chain reaction, STAT6 signal transducer and activator of
transcription 6, TP63 tumor protein p63.
Additional file 7: Figure S6. IL13Rα2 knockdown does not affect
in vitro cell proliferation, anchorage-independent growth, or anoikis. (a)
MIV-Luc-shSCR or MIV-Luc-shIL13RA2 cells (4×103) were seeded in 96-well
culture plates in 100 μl complete medium, incubated at 37 °C in a
humidified incubator with 5 % CO2, and allowed to grow up to 96 h. The
number of viable cells at 24, 48, 72, or 96 h was determined by using an
MTS assay and absorbance at 490 nm. (b) Soft agar colony formation
assay was performed by seeding 5×103 MIV-Luc-shSCR or MIV-Luc-
shIL13RA2 cells in 0.35 % low melting agarose-medium solution on top
of a 0.5 % base agar layer. Plates were incubated in a humidified CO2
incubator for 14 days. Colonies formed were stained by using 0.5 % crystal
violet in 20 % methanol solution and counted. (c) MIV-Luc-shSCR or MIV-
Luc-shIL13RA2 cells were seeded on a 96-well ultra-low attachment plate at
low density (4×103 or 8×103 cells) in 100 μl complete medium. Cells were
incubated at 37 °C in a humidified incubator with 5 % CO2 and allowed togrow for 48 or 96 h. The number of viable cells at 24, 48, 72, or 96 h was
determined by using an MTS assay and absorbance at 490 nm. All
experiments were performed in triplicates, and statistical significance was
assessed by using Student’s t test. IL13Rα2 interleukin-13 receptor alpha 2,
STAT6 signal transducer and activator of transcription 6, TP63 tumor protein
p63.
Additional file 8: Figure S7 IL13Rα2 silencing does not affect breast
cancer cell colonization in the lungs. (a) Comparison of the number of
macroscopic nodules in the right lung of non-obese diabetic/severe
combined immunodeficient mice injected with 5×105 MIV-Luc-shSCR or
MIV-Luc-shIL13Rα2#2. Cells were inoculated directly into the right lung of
mice by injection into the upper margin of the sixth intercostal rib on
the right anterior axillary line, as previously described [47]. Animals
(n = 4) were monitored daily over a period of up to 52 days, and each
mouse was euthanized when it developed notable cachexia symptoms.
When mice were sacrificed, the lungs were excised and the number of
macroscopic nodules in the right lung was counted and compared
between the two groups. (b) Survival curves for the two animal groups
were generated on the basis of the days that mice were euthanized.
Statistical significance was assessed by using Student’s t test. IL13Rα2
interleukin-13 receptor alpha 2, NS not significant, shIL13Rα2 small hairpin
RNA against interleukin-13 receptor alpha 2, shSCR scrambled small
hairpin RNA.
Additional file 9: Figure S8. IL13Rα2 depletion and IL-13 treatment
additively suppress breast cancer cell migration. Representative images
from transwell migration assays. Cells proficient or deficient in IL13Rα2,
treated with 20 ng/ml IL-13 for 48 h or not, that were localized on the
bottom membrane surface were stained with trypan blue (0.4 %) in order
to quantify their migratory potential. IL-13 interleukin-13, IL13Rα2
interleukin-13 receptor alpha 2.
Additional file 10: Figure S9. Kaplan-Meier survival plot analysis for
STAT6 and TP63. (a) Kaplan-Meier relapse-free survival (RFS) plots for patients
with breast cancer were generated by using the Kaplan-Meier Plotter online
tool [24] based on data stratified based on the median tumor expression of
STAT6 and TP63 individually or based on their median expression
combined. (b) Distant metastasis-free survival (DMFS) analysis of patients
with breast cancer, based on the median tumor expression of STAT6 and
TP63 individually. All curves were compared by log-rank test. STAT6 signal
transducer and activator of transcription 6, TP63 tumor protein p63.
Additional file 11: Table S1. List of differentially expressed genes
between MIV-shSCR (−IL13) VS MIV-shSCR (+IL13) cells. shSCRscrambled
small hairpin RNA.
Additional file 12: Table S2. List of differentially expressed genes
between MIV-shSCR (−IL13) VS MIV-shIL13RA2 (−IL13) cells. shIL13Rα2
small hairpin RNA against interleukin-13 receptor alpha 2, shSCR
scrambled small hairpin RNA.Abbreviations
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